Hematology Licensing Deal Calculator —
benchmark your deal in 60 seconds
Phase 2 hematology deals median ~$70M upfront, ~$1B total. CAR-T and bispecifics command 2–3x premiums on upfront. Built on 1,900+ verified biopharma transactions across 12 therapeutic areas.
Hematology deal benchmarks at a glance
Median deal terms for hematology licensing transactions, by development phase. Data current as of 2026.
| Phase | Median Upfront | Median Total Value | Median Royalty (Tiered) |
|---|---|---|---|
| Preclinical | $30M | $700M | 4–9% |
| Phase 1 | $75M | $1.3B | 5–11% |
| Phase 2 | $200M | $2.4B | 8–15% |
| Phase 3 | $500M | $5.5B | 11–20% |
Source: Ambrosia Benchmarker dataset, 1,900+ verified transactions (2017–2026). Primary sources: SEC EDGAR 8-K filings, FTC premerger notifications, ClinicalTrials.gov.
Recent comparable deals
- BMS–Celgene ($74B, CAR-T pipeline)
- AbbVie–ImmunoGen ($10.1B Elahere)
- Pfizer–Seagen ($43B ADC platform)
Why Hematology is priced this way
CAR-T (hematologic), bispecific T-cell engagers, and BCL-2 follow-ons dominate hematology dealmaking. Phase 1/2 readouts in CAR-T can trigger 5-10x re-rating.
Try it live
Run a Hematology deal scenario
Pick your phase, modality, and indication. Get instant benchmark ranges — no signup needed to start.
Quick Benchmark
Live data from 1,900+ deals. Select your parameters:
Hematology licensing — frequently asked
What is the median upfront payment for a Hematology licensing deal?
How are Hematology deal milestones structured?
What royalty rates are typical for Hematology licensing?
Is there a free Hematology deal calculator?
How does Hematology licensing compare to other therapeutic areas?
7-Day Free Trial · No Promo Code
Run unlimited hematology deals — Pro.
Monte Carlo sensitivity, partner matching across 850+ companies, scenario comparison (Bear/Base/Bull rNPV), and board-ready PDF reports. Free for 7 days. Cancel anytime.
Then $299/month · No charge during trial · Cancel anytime